4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $487,738 | $207,490 | $180,053 | $300,467 |
| - Cash | $48,555 | $77,159 | $133,526 | $149,336 |
| + Debt | $22,263 | $23,077 | $23,853 | $24,606 |
| Enterprise Value | $461,446 | $153,408 | $70,380 | $175,737 |
| Revenue | $90 | $15 | $14 | $1 |
| % Growth | 500% | 7.1% | 1,300% | – |
| Gross Profit | -$47,148 | -$47,936 | $14 | -$1,783 |
| % Margin | -52,386.7% | -319,573.3% | 100% | -178,300% |
| EBITDA | -$55,615 | -$58,290 | -$51,867 | -$61,038 |
| % Margin | -61,794.4% | -388,600% | -370,478.6% | -6,103,800% |
| Net Income | -$56,876 | -$54,658 | -$47,972 | -$49,671 |
| % Margin | -63,195.6% | -364,386.7% | -342,657.1% | -4,967,100% |
| EPS Diluted | -1.01 | -0.98 | -0.86 | -0.9 |
| % Growth | -3.1% | -14% | 4.4% | – |
| Operating Cash Flow | -$46,498 | -$43,377 | -$47,758 | -$45,863 |
| Capital Expenditures | $91 | -$66 | -$631 | -$949 |
| Free Cash Flow | -$46,407 | -$43,443 | -$48,389 | -$46,812 |